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Abstract 
Tumor necrosis factor alpha (TNF‑α) is a proinflammatory cytokine with an important role in the pathogenesis of sev‑
eral diseases. Its encoding gene is located in the short arm of chromosome 6 in the major histocompatibility complex 
class III region. Most of the TNF‑α gene polymorphisms are located in its promoter region and they are thought to 
affect the susceptibility and/or severity of different human diseases. This review summarizes the data related to the 
association between TNF‑α gene and its receptor polymorphisms, and the development of autoimmune diseases. 
Among these polymorphisms the −308G/A TNF‑α promotor polymorphism has been associated several times with 
the the development of autoimmune diseases, however some discrepant results have been recorded. The other 
TNF‑α gene polymorphisms had little or no association with autoimmune diseases. Current results about the mol‑
ecules controlling TNF‑α expression are also presented. The discrepancy between different records could be related 
partly to either the differences in the ethnic origin or number of the studied individuals, or the abundance and activa‑
tion of other molecules that interact with the TNF‑α promotor region or other elements.
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Background
Tumor necrosis factor (TNF), first termed by O’Malley 
et  al. (1962), was initially reported to induce pro-
grammed cell death or apoptosis. Currently, this mol-
ecule is thought to be involved in the regulation of many 
important cellular processes such as proliferation, dif-
ferentiation, growth, and the immune response (Hayashi 
et al. 2013). TNF-α is produced by various types of cells 
including macrophages, monocytes, neutrophils, T cells, 
and NK-cells. The gene encoding TNF-α is located in 
the class III region of the major histocompatibility com-
plex on chromosome 6 between the HLA-B and HLA-
DR genes (Zhang et  al. 2013). TNF binds to two types 
of outer membrane bound receptors on the target cells, 
TNFR1 and TNFR2, and triggers the cell survival and 
proinflammatory NF-κB and MAP kinases activations 
(Locksley et  al. 2001). The molecule activates phago-
cytes to engulf and clear infectious agents and cellular 
debris (Elahi et al. 2009). It also increases the expression 
of adhesion molecules on the vascular endothelium to 
allow immune cells, in particular neutrophils and mac-
rophages, to translocate to the sites of tissue damage and 
infection (Barbara et al. 1996).
The roles that TNF-α play seem to be contradictory 
and this was related to the genetic polymorphisms in the 
genes regulating its production and effect (Elahi et  al. 
2009), and the polymorphisms in TNF locus itself. It has 
been reported that the genetic alterations in the TNF-α 
locus are involved in high TNF-α production (Tsuka-
moto et al. 1998).
Several TNF-α polymorphisms have been identified 
inside the TNF-α promoter at the positions, relative to 
the transcription start site, −1031 (T/C), −863 (C/A), 
−857 (C/A), −851 (C/T), −419 (G/C), −376 (G/A), 
−308 (G/A), −238 (G/A), −162 (G/A), and −49 (G/A) 
(Elahi et al. 2009).
In this article, we review the association between the 
genetic polymorphisms in TNF-α and the development 
of autoimmune diseases, and the relation between these 
polymorphisms and TNF-α expression.
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Polymorphisms in TNF‑α receptors
TNF-α interacts with the TNF receptors TNF-RI and 
TNF-RII (Bayley et al. 2003). TNF-α receptors (TNF-Rs) 
are active both in membrane-bound and soluble forms, 
and the soluble receptors act as physiological attenua-
tors of TNF activity (Aderka 1996). With respect to their 
chromosomal location, TNF-RI gene is located at 12p13 
and the TNF-RII gene is located at 1p36.2 (Bayley et al. 
2003).
With respect to the relation between TNF-Rs and auto-
immune diseases, no association was reported between 
TNF-RI +36 and rheumatoid arthritis (RA) in Dutch and 
UK Caucasian population as approved by Bayley et  al. 
(2003) and Barton et al. (2001) respectively. No associa-
tion was found between the TNF-RII +1690 polymor-
phism and susceptibility to or severity of RA in the Dutch 
population (Bayley et al. 2003).
However, TNF-RII 196M/R SNP was found to be asso-
ciated with susceptibility to familial RA (Barton et  al. 
2001; Dieude et  al. 2002), but not associated with spo-
radic RA severity in Caucasian patients (Van der Helm-
van Mil et al. 2004). Glossop et al. (2003) and Constantin 
et al. (2004) have reported conflicting results about con-
sidering TNF-RII 196 M/R SNP as a genetic factor in RA 
severity. The 676TT genotype of TNF-α RII was related 
to a better response to anti-TNF-α drugs when compared 
to 676TG (Ongaro et al. 2008).
Association between TNF‑α genetic polymorphisms 
and autoimmune diseases
Systemic lupus erthymatosus (SLE)
In SLE patients, an increased level of TNF-α was 
reported and strongly correlated with the parameters 
of disease activity (Studnicka-Benke et  al. 1996). A sig-
nificant genetic association between TNF-α promoter 
−308A/G polymorphism and SLE susceptibility in Asian 
populations, and in European-derived populations was 
detected in Zou et al. (2011) and Lee et al. (2006) meta-
analysis respectively.
The −308A allele of TNF-α was associated with the 
production of TNF-α and susceptibility to SLE (Rood 
et  al. 2000; Sullivan et  al. 1997). This allele contributed 
to susceptibility to SLE in South African patients (Wang 
et al. 1999).
Piotrowski et  al. (2015) indicated the presence of sig-
nificant contribution of TNF-α −308 A allele to arthritis 
and renal SLE manifestation, and that the TNF-α −308 
G/A polymorphism may be a HLA-DRB1*03:01 haplo-
type-dependent genetic risk factor for SLE in a cohort of 
Polish population.
The +489A allele of TNF-α was also thought to have 
a genetic contribution to the susceptibility to SLE in the 
Chinese population (Lin et al. 2009).
Rheumatoid arthritis (RA)
TNF-α is thought to play a central role in inflammation 
and it has been directly implicated in the pathogenesis 
of RA (Feldmann et  al. 1990). High concentrations of 
TNF-α were detected in serum and synovial fluid of RA 
patients and TNF-α blood concentration correlated with 
RA disease activity (Nemec et al. 2008).
Studies on the association between −238G/A and 
−308G/A TNF polymorphisms and Juvenile Idiopathic 
Arthritis (JIA) showed conflicting results. For example, 
the −238 G/A polymorphism did not have an effect on 
the patients’ outcome in either Turkish or Czech patients 
while the −308 G/A polymorphism was significantly 
associated with a poor outcome in the Turkish group but 
not in the Czech patients (Ozen et al. 2002) or with sys-
temic JIA in Japanese population (Date et al. 1999). How-
ever, TNF-α −308A allele was significantly associated 
with JIA (JimÊnez-Morales et al. 2009), with systemic JIA 
(Modesto et  al. 2005). Date et  al. (1999) demonstrated 
that the −863A, −1013C, and −857T alleles were signifi-
cantly higher in systemic JIA Japanese patients.
TNF-α was also considered as a major candidate gene 
in psoriatic arthritis (PsA) (Kane and FitzGerald 2004) 
as TNF-α was present in high levels in serum, synovial 
fluid, and synovial membrane in patients with PsA (Dan-
ning et al. 2000; Partsch et al. 1997). However, studies on 
the association between TNF-α polymorphisms and PsA 
showed conflicting results. A strong association between 
−308G/A and −238G/A promoter polymorphisms and 
susceptibility to PsA was demonstrated in some studies 
(Mössner et  al. 2005; Rahman et  al. 2006). In contrast, 
Murdaca et al. (2014) did not find significant association 
between −238 and −308G/A SNPs and PsA in Italian 
patients but they found a significant association between 
+489A allele and both PsA susceptibility and severity. 
Rahman et  al. (2006) could not detect any significant 
association between −1031T/C, −863C/A and −857C/T 
SNPs and PsA.
Also, studies on the relation between TNF-α polymor-
phisms and RA showed conflicting results. For example, 
susceptibility to RA was associated with the −308A allele 
in some studies (JimÊnez-Morales et  al. 2009; Lee et al. 
2007), with the G allele in others (Mosaad et  al. 2011), 
but neither with A allele nor G allele in others (Ates et al. 
2008; Gambhir et  al. 2010; Khanna et  al. 2006; Nemec 
et al. 2008; Rezaieyazdi et al. 2007).
Heterozygous genotype GA of −308A/G SNP was 
found to be associated with more severe course of RA 
disease (Cvetkovic et al. 2002), with increased number of 
erosions, and with the progression of radiographic dam-
age in patients with early seropositive RA (Khanna et al. 
2006). RA severity was associated with the presence of 
−308A allele (Mosaad et  al. 2011; Rodríguez-Carreón 
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et  al. 2005) and with −308G allele (Nemec et  al. 2008). 
The −308G allele showed a trend toward worse radio-
logical outcome by 5 years in patients with inflammatory 
arthritis as indicated by the presence/absence of erosions 
(Barton et al. 2004). In Han Chinese population, suscep-
tibility of RA increased in patients with TNF-α −308G 
allele, especially in the females, and the patients contain-
ing both HLA-DRB1*04 and TNF-α–308 GG genotype 
showed a significant increase in risk for RA regardless of 
their sex (Li et al. 2015). On the other hand, in a cohort 
of Argentinean patients with RA, the −308A allele was 
neither associated with suscetibility to RA nor with the 
course and outcome of the disease (Aranda et al. 2014). 
In addition, there was no significant association between 
−308 G/A polymorphism and RA risk in a cohort of Bul-
garian population (Manolova et al. 2014).
−238G/A polymorphism was associated with more 
severe course of RA (Fabris et al. 2002), however, Barton 
et  al. (2004) showed that both −238G/A and −376G/A 
were not associated with RA severity. No association 
was reported between −238G/A and −376G/A poly-
morphisms and susceptibility to RA in Egyptian popu-
lation (Mousa et  al. 2014). Barton et  al. (2004) failed to 
find any difference in either allele or genotype frequences 
of −1031, −863, −857, +489, +851 and +1304 SNPs 
between patients with inflammatory arthritis developing 
erosions and those remaining non erosive at 5 years.
Fonseca et  al. (2007) demonstrated an association 
between −238, −308, −857, and −863 SNPs and sys-
temic manifestations, functional status, radiological 
damage, work disability, and joint surgeries.
Ankylosing spondylitis (AS)
TNF-α level in blood and its expression by peripheral 
T cells correlated well with AS activity (Bal et  al. 2007; 
Rudwaleit et  al. 2001). Studies on the relation between 
TNF-α SNPs and AS have shown controversial results. 
For example, TNF-α polymorphisms had no independ-
ent effect on AS susceptibility (Chung et al. 2011; Li et al. 
2010) but their modulating effect on TNF-α expression 
were well relevant to the phenotypic diversity in AS (Lee 
and Song 2009; Poddubnyy et al. 2011). In contrast, Var-
gas-Alarcón et al. (2006) and Shiau et al. (2007) showed 
an association of −308G/A polymorphism with suscep-
tibility to AS. Moreover, the A allele was thought to have 
a protective role against AS (Chung et  al. 2011; Nos-
sent et al. 2014), and was associated with a lower risk of 
developing AS, and with the age at disease onset, disease 
severity and response to anti-TNF treatment (Manolova 
et al. 2014).
In conclusion, the data from the studies on TNF-α 
genetic polymorphisms seem to vary from one study to 
another. This variation could be related to the differences 
in the ethnic orgin or the number of the indivisulas under 
study. Although these polymorphisms do affect the 
expression level of TNF-α, the activation and abundance 
of other molecules that interact directly or indirectly with 
the promotor sequence must affect the expression of 
TNF- α.
Control of TNF‑α gene expression
Several studies tried to address the relation between 
TNF-α polymorphisms and its expression, and the 
mechanisms controlling its expressions in many cell 
types and diseases. High TNF-α expression level was 
associated with the −238G allele in multiple sclero-
sis patients (Huizinga et al. 1997) and with −863A and 
−1031C alleles in healthy Japanese and non-Japane-
ses individuals (Higuchi et  al. 1998). While the −238A 
allele was reported to down regulate TNF-α expression 
(Kaluza et  al. 2000). In appearently healthy individu-
als, van Heel et al. (2002) demonstrated that the −857T 
(but not the −857C) allele inhibits TNF-α transcription 
through its strong binding with the transcription factor 
OCT1, which blocks the interaction of nuclear factor-
kappa-B (NF-κB) to the nearby region −873 to −863 
(Fig. 1).
Mousa et  al. (2014) detected a significant increase of 
TNF-α expression in RA patients compared to healthy 
individuals, but this increase in expression was not linked 
to a certain allele of the −238G/A and −376G/A SNPs. 
Besides, several polymorphisms in some TNF-linked 
genes were also thought to regulate the expression of 
TNF directly or indirectly (Abraham and Kroeger 1999).
According to Liu and Shuai (2008), TNF-α can be 
autoregulated by activating PIAS1 [a member of the pro-
tein inhibitor of activated STAT1 (signal transducer and 
activator of transcription 1) family] SUMO E3 ligase. It is 
though that once activated, PIAS1 is then recruited to the 
TNF-α gene promoter to repress transcription (Liu and 
Shuai 2008).
The neurohormonal molecule, angiotensin II (Ang II), 
was thought to play a role in up regulation of TNF-α gene 
expression as Ang II activates two transcriptional factors 
that are important in mediating TNF-α gene expression, 
nuclear factor (NF)-kB and activator protein-1 (AP-1) 
(Chua et  al. 1998; Hernandez-Presa et  al. 1997; Ruiz-
Ortega et al. 1998) (Fig. 1). Angiotensin II also provokes 
TNF biosynthesis in various nonmyocyte cell types (Fer-
reri et al. 1998; Klahr and Morrissey 1998).
Oxidized low density lipoprotein (LDL) and LDL were 
demonstrated to decrease TNF mRNA expression in NK 
cells (Malorni et  al. 1997). Mitogen-activated Protein 
Kinase (MAPK) has been found to play a central role 
in the induced TNF-α expression in monocytes, mac-
rophages, mast cells and T cells (Hoffmeyer et  al. 1999; 
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Ishizuka et  al. 1997; Swantek et  al. 1997; Zhang et  al. 
1997; Zhu et al. 2000).
The 3′ UTR of TNF-α contains a sequence element 
that is though to affect posttranslational control of TNF 
through mRNA stability and translation efficiency (Elahi 
et al. 2009). TNF mRNA has two protein-binding regions 
(Hel et  al. 1998, 1996) located in the AU-rich element 
(ARE) within 3′ UTR (Garnon et  al. 2005). Both AREs 
were reported to interact with several proteins including 
TIAR and AUF1 (DeMaria and Brewer 1996; Gueydan 
et  al. 1999) which control TNF mRNA post transcrip-
tion. Pituitary adenylate cyclase-activating polypeptide is 
another protein that was found to inhibit TNF-α expres-
sion (Manecka et al. 2014).
cAMP has been reported to play an important role in 
regulating TNF-α expression, for example the elevation 
of cellular cAMP suppresses TNF-α production (Gob-
ejishvili et al. 2006; Zidek 1999).
Interferon regulatory factor-5 (IRF5) has been also 
reported to play a key role in the induction of TNF-α 
(Barnes et  al. 2002). Krausgruber et  al. (2010) has 
reported that TNF secretion in human monocyte-derived 
dendritic cells is mediated by cooperative action of IRF5 
and RelA at the 5′ upstream and 3′ downstream regions 
of the TNF gene.
In conclusion, the expression of TNF-α seems to be 
controlled by the activation of other cellular molecules 
including signal transducer molecules, nuclear fac-
tors and second messenger molecules. More studies to 
address the interaction between these molecules and 
TNF-α are required to finally map a TNF-α pathway. 
Profiling the expression of the key molecules inside such 
pathway can open an avenue to control TNF-α over or 
downregulation.
Conclusion
TNF-α plays an important role in the pathogenesis of 
autoimmune diseases. Several studies show that TNF-α 
gene promoter polymorphisms affect the susceptibility 
and/or severity of autoimmune diseases. Polymorphisms 
in the TNF receptors does not seem to be associated with 
the development of autoimmune diseases. The −308 
G/A TNF-α promotor polymorphism seems to be highly 
associated with the development of these diseases, how-
ever some discrepant results have been recorded. Other 
TNF-α gene polymorphisms had little or no association 
Fig. 1 Schematic representation showing some of the molecules thought to be involved in the interaction with TNF‑α promoter region. The tran‑
scriptional induction of TNF‑α is thought to be controlled by some transcription factors, including the transcription factor OCT1, the nuclear factor 
κB (NF‑κB), the signal transducer and transcription activator (PIAS1) and activator protein‑1 (AP‑1). The transcription factor OCT1 can strongly bind 
with the allele ‑857T (but not the ‑857C) and thus blocks the interaction of NF‑κB to the nearby region ‑873 to ‑863 leading to inhibition of TNF‑α 
transcription. PIAS1 possesses SUMO E3 ligase activity and can repress NF‑κB by blocking the DNA‑binding activity of NF‑κB to TNF‑α promoter. Ang 
II can activate the 2 transcription factors NF‑kB and AP‑1that are important in mediating TNF‑α gene expression. Alleles associated with upregula‑
tion of TNF‑α gene are designated with arrows with heads directed up while those alleles associated with downregulation are designated with 
arrows with heads directed down. Molecules involved in the posttranscriptional and posttranslational control of TNF‑α are mentioned in the text 
and not shown here
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with autoimmune diseases. This discrepancy might be 
explained by the differences in the ethnic orgin or num-
ber of the studied individuals. TNF-α gene expression is 
controlled by the presence of some polymorphisms in its 
promoter region and by several types of signalling mol-
ecules or nuclear factors that interact with the TNF-α 
promotor region or other elements.
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